9:22 AM
Leo Group India
| ||
| Zydus Pharmaceuticals Selects Revitas(TM) Flex(TM) Platform to Support Growth ... MarketWatch (press release) PHILADELPHIA, May 03, 2012 (BUSINESS WIRE) -- Revitas announced today that Zydus Pharmaceuticals USA, Inc., a globally integrated generic pharmaceutical company, has selected the strategic Revitas(TM) Flex(TM) technology platform to support the ... See all stories on this topic » | ||
| Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From ... MarketWatch (press release) MONTREAL, May 3, 2012 /PRNewswire via COMTEX/ -- Valeant Pharmaceuticals International, Inc. announced today that Valeant has agreed to acquire certain assets from University Medical Pharmaceuticals Corp., a specialty pharmaceutical company focused on ... See all stories on this topic » | ||
| Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results MarketWatch (press release) Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TOR:CA:VRX) announces first quarter financial results for 2012. "We are pleased to see a solid start to what we expect will be another strong year for Valeant," said J. Michael Pearson, ... See all stories on this topic » | ||
| Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing MarketWatch (press release) PARSIPPANY, NJ, May 03, 2012 (BUSINESS WIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has secured a $27.5 million debt financing facility through Oxford Finance. Pacira will use the proceeds from this financing to refinance ... See all stories on this topic » | ||
| Cardinal profit beats, pharmaceutical unit strong Reuters N) reported higher-than-expected quarterly earnings on Thursday as strength in its pharmaceutical business offset weakness in its much smaller medical products operation. The drug wholesaler also raised the lower end of its forecast for the full fiscal ... See all stories on this topic » | ||
| Novartis to buy Fougera for $1.53 billion Reuters India VX) said on Wednesday it has agreed to buy Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.53 billion in cash. Novartis, which will fold the acquisition into its Sandoz generics unit, said it expects the deal to close in the ... See all stories on this topic » | ||
| Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic ... Reuters Novartis International AG / Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the ... See all stories on this topic » | ||
| Ohr Pharmaceutical to Present at ARVO Annual Meeting on May 6, 2012 MarketWatch (press release) NEW YORK, NY, May 03, 2012 (MARKETWIRE via COMTEX) -- Ohr Pharmaceutical Inc. (OBB:OHRP) announced today that a poster presentation on its Squalamine eye drop program for the treatment of wet-AMD has been selected for presentation at the Association ... See all stories on this topic » | ||
| Sandoz gains dermatology lead with Fougera Financial Times By David Gelles and Alan Rappeport in New York Novartis's generic drugs division Sandoz has agreed to buy Fougera Pharmaceuticals for $1.53bn in cash in a deal that creates the world's biggest generics company focused on dermatology medicines. See all stories on this topic » | ||
| Surya Pharmaceutical Limited Moneycontrol.com Rajiv Goyal has submitted to the Exchange vide its letter dated April 30, 2012 a revised copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Powerful mix of both trader ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment